Category
Cardiovascular and metabolic diseases
153 articles in this topic.
Articles in this category

11/16/2026
CHMP November 2026 Recommends Seven New Medicines for Approval
EMA's CHMP recommended seven new medicines and 11 indication extensions at its 9 to 12 November 2026 meeting, and confirmed two refusals after re-examination.
Read Article →
11/16/2026
Baxfendy EU Positive Opinion: CHMP Backs AstraZeneca’s Hypertension Tablet
The CHMP recommended granting a marketing authorisation for AstraZeneca's Baxfendy (baxdrostat) for insufficiently controlled hypertension. The European Commission makes the final decision. #SyenzaNews #MarketAccess
Read Article →
11/10/2026
Factor XIa Inhibitor for Stroke Prevention: FDA Approves Sunharbo
The FDA approved Sunharbo (asundexian), the first factor XIa inhibitor for stroke prevention, for adults after a recent ischemic stroke or high-risk TIA. #SyenzaNews #MarketAccess
Read Article →
11/3/2026
Mayo Clinic’s TV question for the home blood pressure monitor
A Mayo Clinic cardiologist's TV-set question makes the case for a home blood pressure monitor, with a caution on device reliability and home data in the chart.
Read Article →
10/30/2026
Lancet Authors Make the Case for an EU Medical Device Agency
Four authors writing in The Lancet Regional Health - Europe say the Commission's MDR and IVDR simplification proposal keeps the core flaw: notified bodies still decide, one by one, whether innovative devices reach the market. They argue for an EU medical device agency with binding powers over strategy, guidance and advice. #SyenzaNews #MedTech #MedicalDevices #MarketAccess
Read Article →
10/2/2026
FDA Approves Autus Size-Adjustable Valve That Grows With Children
FDA approval of the Autus Size-Adjustable Valve gives children with congenital pulmonary valve disease a pulmonary valve that can be widened as they grow, from 13 millimeters to 22 millimeters. The evidence base is 62 patients and six months of follow-up. #SyenzaNews #medicaldevices #pediatrics #MarketAccess
Read Article →
9/8/2026
Novo Nordisk Halts Ziltivekimab Heart Failure Trials
Novo Nordisk has stopped the two remaining ziltivekimab heart failure trials after a futility review, leaving ARTEMIS as the last anti-inflammatory cardiovascular outcomes bet. #SyenzaNews #MarketAccess #Cardiology #HTA
Read Article →
8/27/2026
Specialist Payment Models: Triple the Cardiac Testing, No Difference in Outcomes
In Alberta, patients of fee-for-service heart specialists receive roughly three times the cardiac testing, with no measurable difference in outcomes. #HealthEconomics #PhysicianPayment #SyenzaNews
Read Article →
8/13/2026
SAGA Trial Supports Statin Discontinuation in Elderly
💊 Is it safe to stop statins in elderly patients for primary prevention?
A recent trial shows that deprescribing statins in older adults without established cardiovascular disease does not increase the risk of adverse outcomes, supporting more individualized prescribing decisions.
Discover the full trial results and implications for clinical practice.
#SyenzaNews #clinicaltrials #pharmaceuticals #costeffectiveness #healthcarepolicy
Read Article →
7/20/2026
Brazil pharmaceutical supply chain vulnerabilities exposed by pandemic disruptions
🔍 How did the pandemic expose critical weaknesses in Brazil’s pharmaceutical supply chain?
From raw-material dependencies to distribution bottlenecks, COVID-19 disruptions laid bare vulnerabilities that continue to threaten medicine availability and market access across the region.
Read the full analysis to see what these lessons mean for building more resilient supply systems.
#SyenzaNews #pharmaceuticals #globalhealth #MarketAccess #healthcarepolicy
Read Article →
7/16/2026
NICE Finerenone HFpEF Approval Advances HFpEF Therapy Options
How is NICE expanding treatment options for HFpEF patients?
The UK’s National Institute for Health and Care Excellence has approved finerenone, giving clinicians a new evidence-based therapy to improve outcomes in heart failure with preserved ejection fraction. This milestone broadens the therapeutic landscape and reinforces the value of targeted drug development.
Read the full analysis.
#SyenzaNews #pharmaceuticals #HealthcareInnovation #innovation #MarketAccess
Read Article →
7/9/2026
Early TAVR Surveillance Cost-Effectiveness Analysis Demonstrates Economic Dominance
Could earlier surveillance after TAVR unlock better outcomes at lower cost? 💡📈
A new analysis finds that proactive early‑post‑TAVR surveillance has the potential to be cost‑effective — and in many modeled scenarios, economically dominant — by improving patient outcomes while reducing downstream costs. The piece highlights key assumptions, sensitivity analyses, and implications for clinicians, payers, and policymakers.
Read the full article to understand the evidence and what it means for adopting early surveillance strategies.
#SyenzaNews #HealthEconomics #HealthTechnology #costeffectiveness #MarketAccess
Read Article →


